Health Care·Biotechnology·$2.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.32 | N/A | -3.23% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.32 | N/A | -3.23% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about ongoing market conditions. They did not provide detailed guidance for future performance.
Management did not provide specific insights into revenue performance.
The company acknowledged challenges in the current market environment.
Veracyte's earnings report shows a loss that was slightly worse than expected, contributing to a 5.13% drop in stock price. Investors may be concerned about the lack of revenue details and the absence of guidance. The defensive tone from management suggests caution moving forward.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AMERICAN INTL GROUP
May 5, 2014